Kuros Biosciences AG (0RHR.L)
LSE · CHF
CHF 20.24 (-4.62%) as of
Key statistics
- EPS (TTM)
- -0.23
- 52-week range
- 1.33 – 21.12
- Beta
- 0.76
- Revenue (TTM)
- 174.93M
- Profit margin
- 5.13%
- Volume
- 1.65k
About Kuros Biosciences AG
Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company provides MagnetOs Granules, an advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold uses to fill bony voids for intervertebral disc space or posterolateral spine; and Attrax, a biphasic calcium phosphate bone grafts that mimic the porous and trabecular structure of cancellous bone, as well as checkmate licensing. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.
- Headquarters
- Schlieren, Switzerland
- Employees
- 213
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.